Objective: to study the severity of carotid artery atherosclerosis in patients with heterozygous familial hypercholesterolemia in the Uzbek population, depending on the level of PCSK-9 and the genetic polymorphism E670G of the PCSK-9 gene.

Material and methods. The study included 57 patients with chronic stable coronary artery disease (SCAD) and familial heterozygous hypercholesterolemia (HeFH, group I). The comparison group consisted of 144 patients with SCAD without HeFH divided into two subgroups: A - statin free before the research (n=63) and B (n=81) who took it as outpatients; control group consisted of 17 healthy people. The level of proprotein convertase subtilisin-kexin type 9 (PCSK-9) was measured with Human Proprotein Convertase 9/PCSK9 ELISA Kit (MULTI SCIENCE, China). The genetic typing of PCSK9 E670G (rs505151) polymorphism was performed by means of the PCR-RFLP method.

Results. A comparison of the results of duplex scanning of carotid arteries in patients with HeFH showed that the carotid intima-media thickness (CIMT) on the left (1.14±0.18 mm, P<0.01) and on the right (1.15±0.16 mm, P<0.01) was higher, than in the comparison group: 1.05±0.17 mm and 1.04±0.18 mm, respectively. The studies revealed a positive correlation between the incidence of Myocardial infarction (MI) in the history in patients with HeFH and the (r=0.38, P<0.05). The CIMT also correlated with an increase in the concentration of PCSK9 (r = 0.31, P <0.05) in the blood and the carriage of the G allele of polymorphism E670G (r = 0.39, P <0.05) of the PCSK9 gene.

Conclusion. Inpatientswithheterozygousfamilialhypercholesterolemia in the Uzbek population a direct correlation was established between Myocardial infarction in the history, the carotid intima-media thickness, an increase in the concentration of PCSK-9 in the blood and the carriage of the G allele of E670G polymorphism of the PCSK9 gene, that allows them to be used as prognostic markers for the risk of development of cardiovascular complications.

Study of the effect of the degree of arterial hypertension (AH) on the severity of the clinical manifestations of chronic venous disease (CVD) of the lower extremities in men of working age.

Material and methods. A comparative analysis of the clinical severity and severity of CVD (diagnosed by CEAP) was performed using the VCSS scale of two groups of male patients with hypertension aged 3055 years. Group 1 - 40 patients with 1 degree of hypertension (SBP 143 (140-147) mmHg, DBP 92 (90-95) mmHg) and group 2 - 34 patients with 2 and 3 degrees of hypertension (SBP 164 (156-179) mmHg, DBP 107 (101-109) mmHg). Comparison of shares is performed using the contingency table using the X² criterion.

Results. Symptoms of chronic venous diseases such as pain, varicose veins, edema and hyperpigmentation, have been reported in the observed patients. Signs with greater severity were not noted. Leg pain (p = 0.047) and edema (p = 0.002) were more often diagnosed in patients with grade 2 and 3 hypertension than in patients with grade 1 hypertension.

Conclusion. The severity of hypertension worsens the clinic of chronic venous diseases in men 30-55 years old.

Oncological and cardiovascular diseases (CVD) hold a leading position among the causes of mortality in many countries of the world, including the Russian Federation [1]. In recent years, a decrease in mortality due to oncologic diseases (OD) is noted around the world thanks to early diagnostics, as well as to the development and implementation of new technologies and therapeutic treatment strategies (chemotherapy, targeted and radiation therapy). Among patients with OD who received chemotherapy and radiation therapy, CVD is one of the leading causes of poor prognosis, including lethal outcomes [2-5]. The long-term cardiotoxic effects of antitumor therapy (chemotherapy, radiation therapy) reduce the survival rate and quality of life of patients who suffer from cancer. Thus, early diagnostics and timely detection of the cardiotoxic effects that follow antitumor treatment is one of the main tasks of cardio-oncology.